Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has experienced a decline in its stock price by -2.80 compared to its previous closing price of 10.73. However, the company has seen a fall of -15.55% in its stock price over the last five trading days. businesswire.com reported 2025-01-02 that CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throu.
Is It Worth Investing in Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Right Now?
The 36-month beta value for RCKT is also noteworthy at 1.01. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for RCKT is 96.86M, and at present, short sellers hold a 13.35% of that float. The average trading volume of RCKT on January 15, 2025 was 1.19M shares.
RCKT’s Market Performance
RCKT stock saw a decrease of -15.55% in the past week, with a monthly decline of -21.99% and a quarterly a decrease of -39.04%. The volatility ratio for the week is 7.08%, and the volatility levels for the last 30 days are 6.15% for Rocket Pharmaceuticals Inc (RCKT). The simple moving average for the last 20 days is -11.65% for RCKT’s stock, with a simple moving average of -45.71% for the last 200 days.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with Wedbush repeating the rating for RCKT by listing it as a “Outperform.” The predicted price for RCKT in the upcoming period, according to Wedbush is $32 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $29. The rating they have provided for RCKT stocks is “Buy” according to the report published on December 18th, 2024.
RCKT Trading at -23.19% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.86% of loss for the given period.
Volatility was left at 6.15%, however, over the last 30 days, the volatility rate increased by 7.08%, as shares sank -17.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.54% lower at present.
During the last 5 trading sessions, RCKT fell by -15.55%, which changed the moving average for the period of 200-days by -61.72% in comparison to the 20-day moving average, which settled at $11.81. In addition, Rocket Pharmaceuticals Inc saw -17.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Militello John, who sale 1,224 shares at the price of $13.05 back on Nov 21 ’24. After this action, Militello John now owns 49,310 shares of Rocket Pharmaceuticals Inc, valued at $15,978 using the latest closing price.
Patel Kinnari, the of Rocket Pharmaceuticals Inc, sale 4,588 shares at $13.05 during a trade that took place back on Nov 21 ’24, which means that Patel Kinnari is holding 392,395 shares at $59,892 based on the most recent closing price.
Stock Fundamentals for RCKT
Current profitability levels for the company are sitting at:
- -26.55 for the present operating margin
- 0.05 for the gross margin
The net margin for Rocket Pharmaceuticals Inc stands at -25.03. The total capital return value is set at -0.77. Equity return is now at value -59.27, with -52.01 for asset returns.
Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -7.49. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -145.4.
Currently, EBITDA for the company is -236.62 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 103.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.05.
Conclusion
In summary, Rocket Pharmaceuticals Inc (RCKT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
